Skip to main content
Erschienen in:

01.02.2023 | editorial

Efficacy of dual checkpoint-blockade in solid tumors, part 1

verfasst von: Dora Niedersüß-Beke, MD, MBA

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Checkpoint inhibition is one of the most important medical discoveries of the 21st century. Not without reason James P. Allison and Tasuku Honjo received the Nobel Prize in medicine 2018 for their work in this field. The idea to fight cancer by activating immune response, e.g., by cytokines or IL‑2, has been around for decades with limited success. In contrast to these unspecific approaches, the idea of checkpoint inhibition (CPI) is to enhance T‑cell activation, leading to tumor elimination. Apart from CPI monotherapy, there is evidence for synergistic efficacy of combination strategies using inhibitors of the PD-L1/PD‑1 axis plus CTLA4, LAG3, and TIGIT, respectively. There is, however, quite variable efficacy of these combinations across many solid tumor entities, which might be due to differences in tumor heterogeneity and resistance mechanisms. …
Metadaten
Titel
Efficacy of dual checkpoint-blockade in solid tumors, part 1
verfasst von
Dora Niedersüß-Beke, MD, MBA
Publikationsdatum
01.02.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00869-8

Weitere Artikel der Ausgabe 1/2023

memo - Magazine of European Medical Oncology 1/2023 Zur Ausgabe